STOCK TITAN

Chemours (NYSE: CC) officer granted 28,488 shares, 2,789 withheld for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Chemours officer Joseph T. Martinko reported two stock transactions involving company common shares. On March 2, 2026, he acquired 28,488 shares at $0.00 per share through a grant classified as a grant, award, or other acquisition. On March 1, 2026, 2,789 shares at $18.24 per share were automatically withheld to cover tax obligations tied to vesting restricted stock units and related dividend equivalent units, and the footnote clarifies that no shares were sold on the market. After these transactions, his directly held and unit-based interests total 53,889.1669 shares, including common stock, restricted stock units, and dividend equivalent units. The RSU grant is scheduled to vest in three equal annual installments beginning on March 1, 2027, providing a staged equity-based compensation stream over time.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Martinko Joseph T.

(Last) (First) (Middle)
C/O THE CHEMOURS COMPANY
1007 MARKET STREET

(Street)
WILMINGTON DE 19801

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Chemours Co [ CC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/01/2026 F 2,789(1) D $18.24 25,401.1669 D
Common Stock 03/02/2026 A 28,488(2) A $0 53,889.1669(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares automatically withheld to satisfy tax obligations on vesting restricted stock units ("RSUs") and dividend equivalent units. Transactions are exempt from Section 16(b) pursuant to Rule 16b-3. No shares were sold.
2. RSU award scheduled to vest in three equal annual installments beginning on March 1, 2027.
3. Includes directly owned shares, RSUs and dividend equivalent units.
Remarks:
President, Thermal & Specialized Solutions
/s/ Eric Stein, Attorney-in-Fact 03/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Chemours (CC) officer Joseph Martinko report?

Joseph Martinko reported an equity grant and a tax-related share withholding. He received 28,488 Chemours common shares at $0.00 per share, and 2,789 shares at $18.24 per share were withheld to cover taxes on vesting RSUs and dividend equivalent units.

Were any Chemours (CC) shares actually sold in Joseph Martinko’s Form 4 filing?

No open-market sale occurred; the filing states that no shares were sold. Instead, 2,789 shares were automatically withheld at $18.24 per share to satisfy tax obligations from vesting restricted stock units and dividend equivalent units, a common administrative disposition method.

How many Chemours (CC) shares and units does Joseph Martinko hold after these transactions?

After the reported transactions, Joseph Martinko’s holdings total 53,889.1669 Chemours-related units. A footnote explains this figure includes directly owned common shares, restricted stock units (RSUs), and dividend equivalent units, reflecting both granted stock and unit-based awards tied to company equity.

What are the vesting terms of Joseph Martinko’s new Chemours (CC) RSU award?

The RSU award associated with the 28,488 acquired shares is scheduled to vest in three equal annual installments. According to the disclosure, vesting begins on March 1, 2027, meaning one-third of the award vests each year over a three-year period starting then.

How is the Form 4 tax-withholding transaction for Chemours (CC) classified?

The tax-withholding entry is coded F, described as payment of tax liability by delivering securities. It is treated as a tax-withholding disposition, not an open-market sale, and is noted as exempt from Section 16(b) under Rule 16b-3 in the footnotes.

What type of acquisition is shown in the Chemours (CC) Form 4 for Joseph Martinko?

The acquisition is coded A and described as a grant, award, or other acquisition of common stock. Martinko received 28,488 shares at $0.00 per share, reflecting equity compensation rather than a cash purchase on the open market.
Chemours Co

NYSE:CC

CC Rankings

CC Latest News

CC Latest SEC Filings

CC Stock Data

2.63B
148.99M
Specialty Chemicals
Chemicals & Allied Products
Link
United States
WILMINGTON